Thierry Van Nieuwenhove, CEO of Quotient Sciences, contributes to Business Reporter's piece on Quotient Sciences, 'Fortifying Pharmaceutical Innovation, from Laboratory to Clinic'.
With a global client base ranging from emerging biotechnology organizations to Fortune 500 pharmaceutical companies, Quotient Sciences offers a compelling solution for innovators seeking speed, efficiency and quality in bringing new therapies to patients.
For 35 years and with operations in the UK and the US, Quotient Sciences has worked on hundreds of products used to treat conditions ranging from cancer to rare diseases. As a contract research, development and manufacturing organization (CRDMO), the company specializes in the early clinical research and development of drug products for clinical trials and prescription medicines.
Thierry Van Nieuwenhove states, “When clients work with us, they access a team that has collectively worked on thousands of new molecules. Experts from different functions are brought together for every project. We consistently hear from clients how much they appreciate input from such a diverse team to advance programs and make more informed decisions.”
Quotient Sciences’ commitment to innovation makes it a vital partner in translating the UK’s scientific excellence into real-world health and economic impact, especially as the sector continues to embrace digital transformation and new applications of artificial intelligence.
Van Nieuwenhove says, “Every project is driven by the knowledge that behind each molecule lies the potential to transform health. Our culture is built on collaboration, learning, science and agility. These are core to meet our mission of bringing molecules to cures, fast.”
Read the full article on the Business Reporter website here.